Epidermal growth factor receptor–targeted molecular therapeutics for head and neck squamous cell carcinoma

AM Egloff, J Grandis - Expert opinion on therapeutic targets, 2006 - Taylor & Francis
AM Egloff, J Grandis
Expert opinion on therapeutic targets, 2006Taylor & Francis
Several molecular-targeted therapeutics have been tested in clinical trials for the treatment
of head and neck squamous cell carcinoma (HNSCC). Of these, therapeutics targeting the
epidermal growth factor receptor (EGFR) have been studied most extensively and some
agents have demonstrated measurable clinical effectiveness. However, molecular studies
designed to define HNSCC patient subcohorts of likely responders to EGFR-targeted
therapy have not identified molecular signatures that correlate with clinical response. Here …
Several molecular-targeted therapeutics have been tested in clinical trials for the treatment of head and neck squamous cell carcinoma (HNSCC). Of these, therapeutics targeting the epidermal growth factor receptor (EGFR) have been studied most extensively and some agents have demonstrated measurable clinical effectiveness. However, molecular studies designed to define HNSCC patient subcohorts of likely responders to EGFR-targeted therapy have not identified molecular signatures that correlate with clinical response. Here, the authors summarise the relevant clinical findings and highlight reported molecular correlative studies for EGFR-targeted therapeutics for HNSCC. The authors focus especially on molecular markers evaluated for association with clinical response and include data from EGFR-targeted clinical studies in other cancer sites that they anticipate will be of interest to the head and neck cancer research and treatment communities.
Taylor & Francis Online
以上显示的是最相近的搜索结果。 查看全部搜索结果